Q1 FY27 results analysis · August 10, 2026
Jubilant Pharmova Ltd (JUBLPHARMA) Q1 FY27 Results Analysis: PAT Plunges 45%, Margin Collapses 410 bps
−45.1%PAT year on year, Rs. 56.50 Cr
Quick summary
Jubilant Pharmova Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 2,229.40 Cr (+17.30% YoY) and PAT growth of -45.10% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | August 10, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 2,229.40 Cr (+17.30% YoY) |
| PAT (Q1) | Rs. 56.50 Cr (-45.10% YoY) |
| EBITDA margin | 11.10% (-410 bps YoY) |
| EPS (Q1) | Rs. 3.57 (-45.00% YoY) |
| Market cap | Rs. 15,339.93 Cr |
| CMP | Rs. 962.70 |
Quarter Snapshot
Revenue grew 17.3% YoY but EBITDA margin collapsed 410 bps to 11.1% and PAT declined 45.1% YoY. Margin pressure from SPECT shortage, Montreal FDA warning letter, and cost inflation overshadowed segment growth. Management's H2 margin recovery guidance faces steep headwinds.
Key Investment Insights
Key Positives
- Revenue grew 17.3% YoY to Rs.2,229.4 Cr
- Radiopharma segment revenue grew 17.7% YoY
- CDMO Sterile Injectables revenue surged 32.4% YoY
- Allergy Immunotherapy grew 12% YoY, gaining market share
- CRDMO margin improved from 8.7% to 10.9%
Risk Factors
- EBITDA margin collapsed 410 bps YoY to 11.1%
- PAT attributable to owners declined 45.1% YoY
- CDMO Sterile Injectables EBIT margin collapsed to 1.4% from 11.0% YoY
- Generics segment swung to EBIT loss of Rs.10.1 Cr
- Radiopharma EBIT margin fell from 11.4% to 7.6% due to SPECT shortage
- Employee costs rose 27.5% YoY, outpacing revenue growth
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.